Insider · CIK 0001277478
Glenn Sblendorio
Files at FOLD (AMICUS THERAPEUTICS, INC.), FDMT (4D Molecular Therapeutics, Inc.), MLYS (Mineralys Therapeutics, Inc.). First filing -, latest -.
In brief
Glenn Sblendorio files SEC Form 4 as director at FOLD (AMICUS THERAPEUTICS, INC.), and also at FDMT (4D Molecular Therapeutics, Inc.), MLYS (Mineralys Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Glenn Sblendorio has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 16 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | FDMT 4D Molecular Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 18, 2026 |
| Apr 27, 2026 | FOLD AMICUS THERAPEUTICS, INC. | DDisposition to issuer Common Stock | -142,564 | $14.50 | $2.1M | 0 | Apr 27, 2026 |
| Apr 27, 2026 | FOLD AMICUS THERAPEUTICS, INC. | DDisposition to issuer Stock Options (right to buy)derivative | -20,000 | - | - | 0 | Apr 27, 2026 |
| Apr 27, 2026 | FOLD AMICUS THERAPEUTICS, INC. | DDisposition to issuer Stock Options (right to buy)derivative | -16,236 | - | - | 0 | Apr 27, 2026 |
| Apr 27, 2026 | FOLD AMICUS THERAPEUTICS, INC. | DDisposition to issuer Stock Options (right to buy)derivative | -19,473 | - | - | 0 | Apr 27, 2026 |
| Apr 27, 2026 | FOLD AMICUS THERAPEUTICS, INC. | DDisposition to issuer Stock Options (right to buy)derivative | -18,574 | - | - | 0 | Apr 27, 2026 |
| Apr 27, 2026 | FOLD AMICUS THERAPEUTICS, INC. | DDisposition to issuer Stock Options (right to buy)derivative | -36,111 | - | - | 0 | Apr 27, 2026 |
| Apr 27, 2026 | FOLD AMICUS THERAPEUTICS, INC. | DDisposition to issuer Stock Options (right to buy)derivative | -45,423 | - | - | 0 | Apr 27, 2026 |
| Apr 27, 2026 | FOLD AMICUS THERAPEUTICS, INC. | DDisposition to issuer Stock Options (right to buy)derivative | -30,474 | - | - | 0 | Apr 27, 2026 |
| Apr 27, 2026 | FOLD AMICUS THERAPEUTICS, INC. | DDisposition to issuer Stock Options (right to buy)derivative | -42,467 | - | - | 0 | Apr 27, 2026 |
| Apr 27, 2026 | FOLD AMICUS THERAPEUTICS, INC. | DDisposition to issuer Stock Options (right to buy)derivative | -74,872 | - | - | 0 | Apr 27, 2026 |
| Feb 19, 2026 | MLYS Mineralys Therapeutics, Inc. | AGrant or award Common Stock | +6,200 | $0.00 | $0 | 6,200 | Feb 20, 2026 |
| Feb 19, 2026 | MLYS Mineralys Therapeutics, Inc. | AGrant or award Stock Optionderivative | +8,300 | $0.00 | $0 | 8,300 | Feb 20, 2026 |
| Jan 5, 2026 | FDMT 4D Molecular Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jan 7, 2026 |
| Jun 5, 2025 | FOLD AMICUS THERAPEUTICS, INC. | AGrant or award Common Stock | +20,414 | $0.00 | $0 | 115,857 | Jun 6, 2025 |
| Jun 5, 2025 | FOLD AMICUS THERAPEUTICS, INC. | AGrant or award Stock Options (right to buy)derivative | +74,872 | $0.00 | $0 | 74,872 | Jun 6, 2025 |
Questions about Glenn Sblendorio
Answered from the filings on this page, as of the latest one.
Is Glenn Sblendorio buying or selling?
Glenn Sblendorio has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Glenn Sblendorio's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Glenn Sblendorio has 0.
Where does Glenn Sblendorio file Form 4?
Glenn Sblendorio has filed Form 4 at FOLD (AMICUS THERAPEUTICS, INC.); FDMT (4D Molecular Therapeutics, Inc.); MLYS (Mineralys Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.